Donepezil: potential neuroprotective and disease-modifying effects

Bibliography

• Cummings JL. Alzheimer's disease. N Engl J Med 2004;351(1):56-67
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
   PubMed Web of Science ®Google Scholar
• Feldmacher DS. Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. Expert Rev Neurother 2004;4:5-16
   PubMed Web of Science ®Google Scholar
• Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol 2005;1(3):527-36
   PubMedGoogle Scholar
• Benjamin B, Burns A. Donepezil for Alzheimer's disease. Expert Rev Neurother 2007;7:1243-9
   PubMed Web of Science ®Google Scholar
• Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007;8:1011-23
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res Mol Brain Res 1998;62:131-40
   PubMedGoogle Scholar
• Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of Abeta(25-35) in rat PC12 cells. Neuroreport 1998;9:1519-22
   PubMed Web of Science ®Google Scholar
• Kimura M, Komatsu H, Ogura H, Sawada K. Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neurosci Lett 2005;391:17-21
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Borroni B, Cattabeni F, et al. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis 2005;19:237-42
   PubMed Web of Science ®Google Scholar
• Fu H, Li W, Lao Y, et al. Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. J Neurochem 2006;98(5):1400-10
   PubMed Web of Science ®Google Scholar
• Solntseva EI, Bukanova JV, Marchenko E, Skrebitsky VG. Donepezil is a strong antagonist of voltage-gated calcium and potassium channels in molluscan neurons. Comp Biochem Physiol C Toxicol Pharmacol 2007;144(4):319-26
   PubMed Web of Science ®Google Scholar
• Beach TG. Muscarinic agonists as preventative therapy for Alzheimer's disease. Curr Opin Investig Drugs 2002;3:1633-6
   PubMedGoogle Scholar
• Wallace WC, Bragin V, Robakis NK, et al. Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Res Mol Brain Res 1991;10:173-8
   PubMedGoogle Scholar
• Beach TG, Potter PE, Kuo YM, et al. Cholinergic deafferentation of the rabbit cortex: a new animal model of Abeta deposition. Neurosci Lett 2000;283:9-12
   PubMed Web of Science ®Google Scholar
• Roher AE, Kuo YM, Potter PE, et al. Cortical cholinergic denervation elicits vascular A beta deposition. Ann NY Acad Sci 2000;903:366-73
   PubMed Web of Science ®Google Scholar
• Rossner S, Ueberham U, Schliebs R, et al. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol 1998;56:541-69
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J 2008;275(4):625-32
   PubMed Web of Science ®Google Scholar
• Sternfeld M, Shoham S, Klein O, et al. Excess “read-though” acetylcholinesterase attenuates but the “synaptic” variant intensifies neurodeterioration correlates. Proc Natl Acad Sci USA 2000;97:8647-52
   PubMed Web of Science ®Google Scholar
• Ben-Shaul Y, Benmoyal-Segal L, Ben-Ari S, et al. Adaptive acetylcholinesterase splicing patterns attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Eur J Neurosci 2006;23:2915-22
   PubMed Web of Science ®Google Scholar
• Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:S12-8
   PubMed Web of Science ®Google Scholar
• Burghaus L, Schutz U, Krempel U, et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 2000;76(2):385-8
   PubMedGoogle Scholar
• Kume T, Sugimoto M, Takada Y, et al. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur J Pharmacol 2005;527(1-3):77-85
   PubMed Web of Science ®Google Scholar
• Takada-Takatori Y, Kume T, Sugimoto M, et al. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006;51(3):474-86
   PubMed Web of Science ®Google Scholar
• Topper R, Gehrmann J, Banati R, et al. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol 1995;89(1):23-8
   PubMed Web of Science ®Google Scholar
• Harkany T, Abraham I, Timmerman W, et al. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000;12(8):2735-45
   PubMed Web of Science ®Google Scholar
• Takada Y, Yonezawa A, Kume T, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003;306(2):772-7
   PubMed Web of Science ®Google Scholar
• Akasofu S, Kimura M, Kosasa T, et al. Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-d-aspartate (NMDA) toxicity. Eur J Pharmacol 2006;530(3):215-22
   PubMed Web of Science ®Google Scholar
• Saxena G, Singh SP, Agrawal R, Nath C. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 2008;581(3):283-9
   PubMed Web of Science ®Google Scholar
• Maurice T, Meunier J, Feng B, et al. Interaction with sigma 1;protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 2006;317(2):606-14
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006;12:3857-76
   PubMed Web of Science ®Google Scholar
• Okamura N, Funaki Y, Tashiro M, et al. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br J Clin Pharmacol 2008;65(4):472-9
   PubMed Web of Science ®Google Scholar
• Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006;149(8):998-1012
   PubMed Web of Science ®Google Scholar
• Tsukada H, Sato K, Kakiuchi T, Nishiyama S. Age-related impairment of coupling mechanism between neuronal activation and functional cerebral blood flow response was restored by cholinesterase inhibition: PET study with microdialysis in the awake monkey brain. Brain Res 2000;857(1-2):158-64
   PubMed Web of Science ®Google Scholar
• Rosengarten B, Paulsen S, Molnar S, et al. Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer patients. J Neurol 2006;253(1):58-64
   PubMedGoogle Scholar
• Ceravolo R, Volterrani D, Tognoni G, et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol 2004;27(4):166-70
   PubMed Web of Science ®Google Scholar
• Chen X, Magnotta VA, Duff K, et al. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits. J Neuropsychiatry Clin Neurosci 2006;18(2):178-85
   PubMed Web of Science ®Google Scholar
• Berthier ML, Green C, Higueras C, et al. A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology 2006;67(9):1687-9
   PubMed Web of Science ®Google Scholar
• Mori T, Ikeda M, Fukuhara R, et al. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 2006;66(6):935-7
   PubMed Web of Science ®Google Scholar
• Zhou J, Fu Y, Tang XC. Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett 2001;306:53-6
   PubMed Web of Science ®Google Scholar
• Xu AJ, Chen Z, Yanai K, et al. Effect of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazapin-8-yl)-1-propanone fumarate, a novel acetylcholinesterase inhibitor, on spatial cognitive impairment induced by chronic erebral hypoperfusion in rats. Neurosci Lett 2002;331:33-6
   PubMed Web of Science ®Google Scholar
• Doganay G, Khodr B, Georgiou G, Khalil Z. Pharmacological manipulation of the vasoconstrictive effects of amyloid-beta peptides by donepezil and rivastigmine. Curr Alzheimer Res 2006;3(2):137-45
   PubMedGoogle Scholar
• Barnes CA, Meltzer J, Houston F, et al. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000;99:17-23
   PubMed Web of Science ®Google Scholar
• Oda T, Kume T, Katsuki H, et al. Donepezil potentiates nerve growth factor-induced neurite outgrowth in PC12 cells. J Pharmacol Sci 2007;104(4):349-54
   PubMed Web of Science ®Google Scholar
• Kotani S, Yamauchi T, Teramoto T, Ogura H. Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience 2006;142(2):505-14
   PubMed Web of Science ®Google Scholar
• Leyhe T, Stransky E, Eschweiler GW, et al. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2008;258(2):124-8
   PubMed Web of Science ®Google Scholar
• Ginestet L, Ferrario JE, Raisman-Vozari R, et al. Donepezil induces a cholinergic sprouting in basocortical degeneration. J Neurochem 2007;102(2):434-40
   PubMed Web of Science ®Google Scholar
• Reid RT, Sabbagh MN. Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. J Alzheimers Dis 2003;5:429-36
   PubMed Web of Science ®Google Scholar
• Shearman E, Rossi S, Szasz B, et al. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res Bull 2006;69(2):204-13
   PubMed Web of Science ®Google Scholar
• Reale M, Iarlori C, Gambi F, et al. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 2005;40(3):165-71
   PubMed Web of Science ®Google Scholar
• Tyagi E, Agrawal R, Nath C, Shukla R. Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. Life Sci 2007;80(21):1977-83
   PubMed Web of Science ®Google Scholar
• Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003;160:2003-11
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005;162:676-82
   PubMed Web of Science ®Google Scholar
• Nakano S, Asada T, Matsuda H, et al. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 2001;42:1441-5
   PubMed Web of Science ®Google Scholar
• Nobili F, Vitali P, Canfora M, et al. Effects of long-term donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 2002;113:1241-8
   PubMed Web of Science ®Google Scholar
• Tune L, Tiseo PJ, Ieni J, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease. Am J Geriatr Psychiatry 2003;11:169-77
   PubMed Web of Science ®Google Scholar
• Van Dam D, Coen K, De Deyn PP. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacoogyl 2007;197:37-43
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Llovo R, Fraile C, Fernandez-Novoa L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res 2007;4(4):479-500
   PubMed Web of Science ®Google Scholar
• Lyle S, Grizzell M, Willmott S, et al. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. Dement Geriatr Cogn Disord 2008;25:226-31
   PubMed Web of Science ®Google Scholar
• Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007;68(20):1726-9
   PubMed Web of Science ®Google Scholar